In 2014, Cochlear was the first company to receive FDA-approval of an expanded hearing loss indication with the introduction of the Nucleus® Hybrid Cochlear Implant system, the first electro-acoustic implant solution intended for adult candidates who meet this new hearing loss indication.
CEUs/Hours Offered: AAA/0.1 Intermediate; ACAud/1.0; ASHA/0.1 Intermediate, Professional; BAA/1.0; CAA/1.0; IACET/0.1; IHS/1.0; Kansas DHE, LTS-S0035/1.0; NZAS/1.0; SAC/1.0
This course will provide participants with an overview of the Hybrid L24 FDA clinical trial results. Specifically, the presenter will review the clinical trial criteria, the study results, current patient performance and programming considerations.
Course Learning Outcomes
- After the completion of this course participants will be able to list the benefits of acoustic hearing.
- After the completion of this course participants will be able to describe the expanded indications for the CochlearTM Nucleus® Hybrid.
- After the completion of this course participant will be able to outline the steps to programming a Nucleus Hybrid Device.
Click here to register.
Ginger Grant, AuD, CCC-A
Principal Clinical Project Manager
Ginger Grant currently works on the Clinical Studies team at Cochlear Americas as a Principal Clinical Project Manager. She first developed an interest in implantable hearing technology and the people for whom it is intended during her CFY at Johns Hopkins and she has continued to feed this passion for over 22 years. During her time at Cochlear she has served in a variety of roles including clinical support specialist, surgical trainer, sales representative, and clinical/technical manager. Dr. Grant received her AuD from Central Michigan University in Mount Pleasant, MI.
The Nucleus® Hybrid™ Implant System is approved in the US for adults 18 and older.
The acoustic component should only be used when behavioral audiometric thresholds can be obtained and the recipient can provide feedback regarding sound quality.
©Cochlear Limited 2017. All rights reserved. Hear now. And always and other trademarks and registered trademarks are the property of Cochlear Limited or Cochlear Bone Anchored Solutions AB. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.